Fortress Biotech (FBIO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
Meeting called to order by the Executive Chairman, President, and CEO, with directors introduced and present via remote communication.
Independent auditors, legal counsel, CFO (serving as Secretary), and Inspector of Elections were introduced.
Agenda included accepting motions, collecting votes, and reporting results.
Shareholder proposals
Two motions presented: election of directors to serve until the 2027 annual meeting and ratification of KPMG as independent auditors for 2026.
Overview of voting outcomes
Quorum confirmed with a majority of shares represented as of the record date.
All director nominees were approved.
Ratification of KPMG as independent auditors for 2026 was approved.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fortress Biotech
- Q2 2026 revenue up 14% to $18.7M, with a $158.9M PRV gain and strong cash reserves.FBIO
Q2 2026 - Triplex delivers robust efficacy and safety in CMV prevention for transplants, targeting $1B+ peak sales.FBIOCorporate presentation
- Proprietary bioreactor boosts MSC potency, enabling lower dosing and major cost savings.FBIOCorporate presentation
- Three FDA approvals, strong revenue, and a robust late-stage pipeline drive near-term growth.FBIOCorporate presentation
- Scalable, royalty-driven model and recent monetizations fuel growth and strengthen financial position.FBIOA.G.P.'s Annual Virtual Healthcare Conference
- Q1 2026 net income jumped to $108.4M on a $205M PRV sale and 21–22% revenue growth.FBIOQ1 2026
- Shareholders will vote virtually on director elections, auditor ratification, and equity-based executive pay.FBIOProxy filing
- Virtual vote set for June 2026 on director elections and auditor ratification.FBIOProxy filing
- Two FDA approvals and a major acquisition highlight Fortress Biotech's transformative 2024.FBIOQ4 2024